Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe
Portfolio Pulse from Vandana Singh
The European Commission has approved Roche Holdings AG's Tecentriq SC, a subcutaneous injection version of its cancer drug Tecentriq, marking it as the EU's first PD-(L)1 cancer immunotherapy for under the skin injection. Tecentriq SC, which uses Halozyme Therapeutics Inc's Enhanze technology, offers a shorter treatment time compared to the IV infusion method. The approval is based on the IMscin001 study results, and the drug is expected to provide more flexibility for patients and help alleviate healthcare system constraints. Halozyme's shares rose 4.10% on the news.
January 16, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics' Enhanze technology is used in the newly approved Tecentriq SC, which could lead to increased royalties or revenues from Roche's sales.
Halozyme's stock price increase reflects the market's positive reaction to the approval of Tecentriq SC, which uses its technology. This could result in higher revenues for Halozyme from Roche, thus positively impacting its stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Roche's Tecentriq SC has been approved by the European Commission, potentially increasing the drug's marketability and patient convenience due to shorter treatment times.
The approval of Tecentriq SC in the EU is likely to have a positive impact on Roche's stock as it could lead to increased usage and sales, given the convenience of the shorter treatment time and the potential for homecare use.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90